Antares Pharma to Report Third Quarter 2020 Financial and Operating Results
October 22, 2020 08:30 ET
|
Antares Pharma, Inc.
EWING, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its third quarter 2020...
Antares Pharma Enters Exclusive License Agreement With Ferring Pharmaceuticals for Nocdurna® in U.S.
October 01, 2020 08:46 ET
|
Antares Pharma, Inc.
EWING, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that it entered into an exclusive license...
Antares Pharma to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference
September 08, 2020 08:00 ET
|
Antares Pharma, Inc.
EWING, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief...
Antares Pharma Appoints Tram Bui as Vice President of Corporate Communications and Investor Relations
August 10, 2020 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced the appointment of Tram Bui as Vice President...
Antares Pharma Reports Strong Second Quarter 2020 Operating and Financial Results; Reinstates Full-Year 2020 Revenue Guidance
August 06, 2020 07:00 ET
|
Antares Pharma, Inc.
Second Quarter 2020 Revenue of $32.4 Million, a 14% Increase Compared to Second Quarter 2019Second Quarter 2020 Net Income of $2.2 Million as Compared to Net Loss of $2.2 Million for Second Quarter...
Antares Pharma and Lunatus Enter Into an Exclusive Distribution Agreement for XYOSTED® in Saudi Arabia and the United Arab Emirates
August 03, 2020 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement...
Antares Pharma to Report Second Quarter 2020 Operating and Financial Results
July 30, 2020 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced it will release its second quarter 2020 financial results and...
First Commercial Product Using Antares Pharma’s Multi-Dose Pen Platform Launches in Europe
July 21, 2020 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of the...
Antares Pharma Appoints Patrick Shea Senior Vice President of Commercial
July 20, 2020 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced the appointment of Patrick Shea to the...
Antares Pharma to Present at the Raymond James Human Health Innovation Conference
June 11, 2020 07:00 ET
|
Antares Pharma, Inc.
EWING, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), today announced that Robert F. Apple, President and Chief Executive Officer, will present at the...